drugset
drugset / Trial / NCT05232110

Compassionate Use of Pozelimab

NCT05232110 ↗

Expanded access Approved for marketing Regeneron Pharmaceuticals

Summary

Provide compassionate use of pozelimab

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Pozelimab Monoclonal antibody — —

Indications

protein-losing enteropathy